IGF-1 LR3 vs HGH (Somatropin)
Modified Growth Factor · Recombinant Growth Hormone
Here is how these two compounds compare, based on published research, not marketing claims.
IGF-1 LR3
A modified IGF-1 with extended half-life that delivers the downstream growth factor directly; research-stage, not FDA-approved.
HGH
The recombinant human growth hormone itself, FDA-approved as somatropin with decades of clinical use across multiple indications.
IGF-1 LR3
43 studies
1 human trials
Not FDA-Approved
HGH
0 studies
0 human trials
Not FDA-Approved
What it does
IGF-1 LR3
Delivers a long-acting form of IGF-1, the growth signal the liver produces in response to growth hormone. Stays active in the body longer than natural IGF-1 because a structural modification reduces how quickly binding proteins clear it.
HGH
Replaces or supplements the body's natural growth hormone, the pituitary signal that controls cellular growth and tissue repair throughout the body. The recombinant human form, FDA-approved as somatropin under multiple brand names including Genotropin, Humatrope, and Norditropin.
How it works
IGF-1 LR3
IGF-1 LR3 is a modified version of insulin-like growth factor 1 with an arginine-to-glutamic acid substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications reduce binding affinity for IGF binding proteins (IGFBPs), extending the biological half-life from minutes to hours. The molecule activates the IGF-1 receptor on muscle, bone, and other tissues, promoting protein synthesis, cell proliferation, and glucose uptake.
HGH
HGH is a 191-amino-acid protein hormone produced by the anterior pituitary gland. The recombinant pharmaceutical form is bioidentical to the body's own version. After injection, it travels through the bloodstream to the liver, where it stimulates production of insulin-like growth factor 1 (IGF-1), the downstream messenger that mediates most of HGH's effects on cellular growth, protein synthesis, and tissue repair. HGH also acts directly on adipose tissue (promoting lipolysis), bones, muscles, and the immune system.
How often
IGF-1 LR3
In published research protocols, IGF-1 LR3 has been administered as subcutaneous or intramuscular injection. No FDA-approved product exists; no standardized clinical dosing protocol has been established through regulatory channels.
HGH
FDA-approved labeling specifies daily subcutaneous injection in clinical use, with dosing individualized to indication, age, weight, and IGF-1 response. Long-acting depot formulations approved more recently allow once-weekly administration in some contexts.
How strong
IGF-1 LR3
Potent anabolic signaling through the IGF-1 receptor pathway. The extended half-life means more sustained tissue exposure per administration compared to unmodified IGF-1. Used extensively in cell culture research and animal models for studying IGF-1-mediated growth pathways.
HGH
The reference standard for growth hormone interventions. FDA-approved for multiple indications spanning pediatric and adult use: pediatric growth hormone deficiency, adult GH deficiency, Turner syndrome, Prader-Willi syndrome, idiopathic short stature, AIDS wasting, short bowel syndrome, and others. Decades of clinical use with extensive safety and efficacy data.
Main tradeoff
IGF-1 LR3
Bypasses the body's natural growth hormone axis entirely. Unlike GH secretagogues that stimulate endogenous production, IGF-1 LR3 supplies the downstream growth factor directly. Hypoglycemia risk is the primary safety concern in animal studies due to direct insulin-like activity. No completed human clinical trials for therapeutic use. Not FDA-approved.
HGH
Direct hormone replacement rather than stimulating endogenous release. The body's natural pulsatile pattern of GH secretion is replaced by the pharmacokinetic profile of the injection. Long-term safety in non-deficient populations using HGH for body composition or anti-aging purposes is poorly characterized. Off-label use of HGH for adult anti-aging or athletic performance is legally restricted in the United States under the Anabolic Steroid Control Act and FDA enforcement policies. Cost and supply considerations are substantial.
Best for
IGF-1 LR3
- Research on IGF-1 receptor signaling and downstream anabolic pathways
- Comparing direct growth factor delivery versus upstream GH stimulation
- Cell culture and animal model studies requiring sustained IGF-1 exposure
HGH
- Patients with diagnosed growth hormone deficiency in pediatric or adult populations under physician supervision
- Patients meeting FDA-approved indications including Turner syndrome, Prader-Willi syndrome, AIDS wasting, and short bowel syndrome
- Researchers comparing direct hormone replacement against strategies that stimulate the body's own GH release
How to choose
A good fit for IGF-1 LR3
- Research on direct IGF-1 receptor signaling independent of the GH axis
- Cell culture and animal model studies requiring sustained IGF-1 receptor activation
- Research comparing downstream effector delivery versus upstream hormone replacement
A good fit for HGH
- Clinical treatment for diagnosed growth hormone deficiency under physician supervision
- Research requiring FDA-approved status and decades of clinical validation
- Research contexts where the full GH cascade (not just IGF-1) is the biological question
Consider both across time
IGF-1 LR3 and HGH target the same growth axis from different positions. HGH engages the full biological cascade: GH receptor activation, liver IGF-1 production, direct effects on adipose tissue, bone, and muscle. IGF-1 LR3 delivers only the downstream growth factor with extended activity. HGH has the weight of FDA approval and decades of clinical data; IGF-1 LR3 remains a research tool with primarily preclinical evidence. The choice depends on whether the research question requires the full GH cascade or isolated IGF-1 receptor activation.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Extended Half-Life sustains activation of IGF-1 Receptor
- Reduced IGFBP Binding
- Reduced IGFBP Binding enables Extended Half-Life
- IGF-1 Receptor activates Protein Synthesis
- IGF-1 Receptor activates Cell Proliferation
- IGF-1 Receptor increases Glucose Uptake
- Protein Synthesis connects to Anabolic Signaling; Cell Proliferation connects to Anabolic Signaling
- GH Receptor (liver, muscle, adipose, bone)
- GH Receptor (liver, muscle, adipose, bone) activates Liver IGF-1 Production
- GH Receptor (liver, muscle, adipose, bone) connects to Direct Tissue Effects (lipolysis, bone, muscle)
- Liver IGF-1 Production connects to IGF-1 Mediated Growth and Repair
- Direct Tissue Effects (lipolysis, bone, muscle) connects to Body Composition Effects
IGF-1 LR3 activates the IGF-1 receptor directly with reduced IGFBP binding, extending the biological half-life from minutes to hours.
HGH is the recombinant human growth hormone itself, bioidentical to the pituitary's natural product, replacing the body's own hormone directly.
Research Evidence
HGH has dramatically more clinical evidence: decades of randomized controlled trials, post-market surveillance across multiple FDA-approved indications (pediatric and adult GH deficiency, Turner syndrome, AIDS wasting, short bowel syndrome), and millions of prescriptions worth of real-world safety data. IGF-1 LR3 is primarily characterized in cell culture and animal models. No completed human therapeutic trials have been published for IGF-1 LR3. Unmodified recombinant IGF-1 (mecasermin, Increlex) is FDA-approved for severe primary IGF-1 deficiency, but IGF-1 LR3 is a structurally different molecule with different pharmacokinetics and no regulatory pathway.
- 1.
For medical GH replacement, HGH is the standard of care with extensive evidence.
- 2.
For research into direct IGF-1 receptor activation, IGF-1 LR3 is a specific research tool.
- 3.
For safety and regulatory confidence, HGH has incomparably more data.
- 4.
IGF-1 LR3 should be understood as a research compound, not a clinical alternative to HGH.
Key Limitations
- •Not a meaningful clinical comparison, one is FDA-approved, the other is a research compound.
- •IGF-1 LR3 bypasses feedback mechanisms that exist for safety reasons.
- •Direct growth factor administration carries theoretical oncogenesis concerns.
- •Cost, legality, and access differ enormously.
Safety Comparison
HGH has the most mature safety profile in the growth hormone field: decades of post-market surveillance from millions of prescriptions. IGF-1 LR3's safety profile is characterized only from preclinical data: hypoglycemia from direct insulin-like activity is the primary concern, with broader questions about sustained cell proliferation signaling from extended IGF-1 receptor activation. Off-label HGH use for adult anti-aging is legally restricted in the United States under the Anabolic Steroid Control Act. IGF-1 LR3 has no regulatory status and no clinical safety monitoring infrastructure.
IGF-1 LR3
Limited safety data. Theoretical concerns about uncontrolled growth factor signaling. Hypoglycemia risk from insulin-like effects. Not FDA-approved.
HGH (Somatropin)
Extensively characterized. Joint pain, edema, carpal tunnel, insulin resistance possible. Decades of monitoring data. Requires prescription.
What the Research Suggests
HGH is the proven medical intervention. IGF-1 LR3 is a research tool. Comparing them for clinical use is misleading. HGH works through normal physiology. IGF-1 LR3 bypasses it.